Hims & Hers Health (NYSE: HIMS) shares fell approximately 6% after hours Monday and extended the decline into Tuesday August 11, 2026 trading despite Q2 2026 revenue of $753.2 million (+38% year-over-year, beating $698.9 million consensus) and Q3 guidance of $890 million at the midpoint (+12.4% above analyst expectations). The GAAP loss of $0.37 per share ran well below analyst estimates, and gross margin compression to 64% (from 76% year-ago) hit its fourth consecutive quarter of decline. Q2 net loss reached $86.3 million versus $42.5 million net income in Q2 2025. The compounded-to-branded GLP-1 pivot through the Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026 continues to drag unit economics. Full-year 2026 guidance was raised to $3.1-3.3 billion revenue and $275-325 million Adjusted EBITDA. The market appears to be pricing the compounded-to-branded pivot as a durable margin drag rather than a transitory transition; the July 29 FTC lawsuit alleging consumer health data sharing with Meta and Snap plus unauthorized billing charges remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the peptide-strategy narrative for the stock.
Hims & Hers Health (NYSE: HIMS) reported Q2 2026 earnings after market close Monday August 10, 2026. Revenue reached $753.2 million (+38% year-over-year), beating consensus of $698.9 million. US revenue was $621.8 million (+16% YoY); international revenue climbed to $131.4 million (+17-fold year-over-year) aided by the completion of the Eucalyptus acquisition in June 2026. Subscribers grew to approximately 2.9 million (+19% YoY). The company raised full-year 2026 guidance to $3.1-3.3 billion in revenue and $275-325 million in Adjusted EBITDA. Net loss was $86.3 million versus $42.5 million net income in Q2 2025 as gross margin compressed to 64% from 76% year-ago; the compression reflects the strategic pivot from compounded GLP-1s (higher margin) to branded GLP-1 supply (lower margin) through Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026. The FTC lawsuit filed July 29 alleging the company shared consumer sensitive health information with Meta Platforms and Snap Inc. through embedded tracking technologies and separately alleging unauthorized billing charges (with Los Angeles County and Utah as co-plaintiffs) remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the post-PCAC peptide-strategy narrative.
Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of the July 29, 2026 Federal Trade Commission (FTC) lawsuit. FTC allegations: the company shared consumer sensitive health information with Meta Platforms, Snap Inc., and other online advertising platforms through embedded website tracking technologies (pixel-based cookie/session tracking) without meeting informed-consent requirements; and separately, that the company charged some patients for prescriptions they did not order. Los Angeles County and Utah joined the FTC as co-plaintiffs, expanding both the geographic exposure and the potential remedy set. HIMS shares dropped 10% on the July 29 announcement. Bank of America analyst Allen Lutz reiterated Hold and cut the price target to $30 from $37 on FTC-lawsuit uncertainty, characterizing the outcome as a small-fee base case. Wall Street consensus for Q2 2026: $698.9 million revenue (+28.3% year-over-year) and -$0.05 diluted EPS loss versus the +$0.17 year-ago quarter. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas: peptide-compounding revenue trajectory (Leerink pegs $440M peptide sales for full-year 2026), FTC lawsuit financial and operational impact, and branded GLP-1 partnership contribution since Q1 2026.
Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of a Federal Trade Commission (FTC) lawsuit alleging the company shared consumer sensitive health information with third-party advertising platforms without meeting HIPAA-compatible informed-consent requirements. Wall Street consensus: $698.9 million revenue (+28.3% year-over-year) and approximately -$0.05 diluted EPS loss versus +$0.17 EPS in the year-ago quarter. Bank of America analyst Allen Lutz cut the HIMS price target to $30 from $37 (maintaining Hold), citing FTC-lawsuit uncertainty with a small-fee base-case framing. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas beyond top-line numbers: post-PCAC peptide-compounding revenue trajectory (Leerink estimates $440 million peptide sales in 2026 representing 15% of the projected revenue midpoint); FTC lawsuit financial and operational impact; branded GLP-1 (Wegovy/Ozempic/Zepbound/Mounjaro) commercial partnership contribution since Q1 2026; and Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing for the Hims peptide strategy narrative. Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support given the 12-24 month FDA rulemaking timeline.